{"id":1093,"date":"2011-01-01T12:02:00","date_gmt":"2011-01-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/dabigatran-zur-embolieprophylaxe-bei-vorhofflimmern-in-den-usa-zugelassen"},"modified":"2011-01-01T12:02:00","modified_gmt":"2011-01-01T11:02:00","slug":"dabigatran-zur-embolieprophylaxe-bei-vorhofflimmern-in-den-usa-zugelassen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2011\/dabigatran-zur-embolieprophylaxe-bei-vorhofflimmern-in-den-usa-zugelassen","title":{"rendered":"Dabigatran zur Embolieprophylaxe bei Vorhofflimmern in den USA zugelassen"},"content":{"rendered":"<p>Dabigatran (Pradaxa\u00ae) wurde &#8211; erwartungsgem\u00e4\u00df &#8211; von der FDA zur Prophylaxe arterieller Embolien bei Vorhofflimmern (VHF) zugelassen. Dies gaben der Hersteller Boehringer Ingelheim und die FDA zeitgleich am 19. Oktober bekannt (1). Im September hatte das zust\u00e4ndige Advisory Panel einstimmig (9 zu 0) die Zulassung des oralen Thrombin-Antagonisten empfohlen. Auch in Europa, wo Dabigatran zur [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dabigatran (Pradaxa\u00ae) wurde &#8211; erwartungsgem\u00e4\u00df &#8211; von der FDA zur Prophylaxe arterieller Embolien bei Vorhofflimmern (VHF) zugelassen. Dies gaben der Hersteller Boehringer Ingelheim und die FDA zeitgleich am 19. Oktober bekannt (1). Im September hatte das zust\u00e4ndige Advisory Panel einstimmig (9 zu 0) die Zulassung des oralen Thrombin-Antagonisten empfohlen. Auch in Europa, wo Dabigatran zur [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,137,184,2305,1314,1312,1324,187,1328,1060,1327,2727,2726,2450,2451,183,54,51,2066,181],"class_list":["post-1093","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-antikoagulanzien","tag-arrhythmien","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-embolie","tag-herzrhythmusstoerungen","tag-neue-orale-antikoagulanzien","tag-niereninsuffizienz","tag-noak","tag-re-ly-studie","tag-re-mobilze-studie","tag-re-model-studie","tag-re-novate-studie","tag-rhythmusstoerungen","tag-thromboembolie","tag-thrombose","tag-thromboseprophylaxe","tag-vorhofflimmern"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1093"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1093\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}